Skip to content Skip to footer
Subscribe Now
PharmaShots Interview Takeda’s Elke Walter & Derek Wallace Share Insights on TAK-003 for Dengue & Zika Viruses
VIEWPOINTS
PharmaShots Interview: Takeda’s Elke Walter & Derek Wallace Share Insights on TAK-003 for Dengue & Zika Viruses
In an interview with PharmaShots, Elke Walter, Senior Director, Global Zika Program Lead & Derek Wallace, Vice President, Global Dengue Program Lead at Takeda share their views on TAK-003 & highlighted 10 presentations from dengue and zika programs at ASTMHShots:The company reported a cumulative safety assessment included long-term safety data from the five…
March 23, 20220Comments
PharmaShots Interview Astellas’ John C. Hairston & Gabriel P. Haas Share Insights on Xtandi (enzalutamide) for the Treatment of Prostate Cancer
VIEWPOINTS
PharmaShots Interview: Astellas’ John C. Hairston & Gabriel P. Haas Share Insights on Xtandi (enzalutamide) for the Treatment of Prostate Cancer
In an interview with PharmaShots, John C. Hairston, Sr. Medical Director, Oncology US Medical Affairs & Gabriel P. Haas, Senior Medical Director, Oncology Development Medical Sciences at Astellas share their views on the data of Xtandi (enzalutamide) over Active Surveillance for Localized Prostate CancerShots:The P-II (ENACT) study evaluates enzalutamide as monothx. vs active…
March 22, 20220Comments
PharmaShots Interview Tillotts Pharma’s Adrian Hill & Christian Weidenfeller Share Insights on Dificlir (fidaxomicin) for the Treatment of Clostridioides Difficile Infection
VIEWPOINTS
PharmaShots Interview: Tillotts Pharma’s Adrian Hill & Christian Weidenfeller Share Insights on Dificlir (fidaxomicin) for the Treatment of Clostridioides Difficile Infection
In an interview with PharmaShots, Adrian Hill, Head of Commercial Operations & Christian Weidenfeller, Global Head of Medical Affairs Anti-Infectives at Tillotts Pharma share their views on the ESCMID recommendation for Dificlir (fidaxomicin) to treat Clostridioides Difficile InfectionShots:·        Clostridioides difficile infection (CDI) is the leading cause of hospital-acquired infection· …
March 21, 20220Comments
PharmaShots Interview Dermavant’s Philip Brown Shares Insight on the P-III (PSOARING 3) Study of Tapinarof
VIEWPOINTS
PharmaShots Interview: Dermavant’s Philip Brown Shares Insight on the P-III (PSOARING 3) Study of Tapinarof
In an interview with PharmaShots, Philip Brown, Chief Medical Officer at Dermavant share his views on the data of Tapinarof in the P-III (PSOARING 3) study for the treatment of Plaque Psoriasis & highlights new patient satisfaction dataShots:The P-III (PSOARING 3) extension study evaluates tapinarof (1%, qd) in adult patients with PsO for ~40wks. & a 4wks. safety follow-up periodThe…
March 15, 20220Comments
PharmaShots Interview Jazz Pharmaceuticals’ Bruce C. Cozadd Shares Insight on Vision 2025 During the Virtual Presentation at 40th Annual J.P. Morgan Healthcare Conference 2022
VIEWPOINTS
PharmaShots Interview: Jazz Pharmaceuticals’ Bruce C. Cozadd Shares Insight on Vision 2025 During the Virtual Presentation at 40th Annual J.P. Morgan Healthcare Conference 2022
In an interview with PharmaShots, Bruce C. Cozadd, Chairman and Chief Executive Officer at Jazz Pharmaceuticals shared his views on Vision 2025 to deliver sustainable growth and enhanced valueShots:The company reported Vision 2025 to deliver sustainable growth and enhanced value to drive the transformation to an innovative, high-growth, global biopharmaceutical leaderThe company is expected to…
March 14, 20220Comments
Biopharma Deal Terminations Top 20 2021
TOP 20
Top 20 Biopharma Deal Terminations of 2021 Based on Total Deal Value
Shots:The biopharma industry saw numerous deal terminations in 2021. Clinical and regulatory results, change of control limitations, and strategic reprioritizations were among the most common reasons for deal termination.SOBI and Advent's acquisition agreement in 2021 ranked first under which Advent International offered to acquire SOBI. The second position goes to Galapagos’ development and…
March 10, 20220Comments